Brought to you by 
Alexza brings in $52mm with venture financing
19 Mar 2013
Executive Summary
Alexza Molecular Delivery, a specialty pharmaceutical company developing products that improve drug delivery, raised $52mm through a private placement of Series D preferred shares. Alloy Ventures and Delphi Ventures co-led the round which included new investors Abingworth Bioventures, MDS Capital, Pacific Rim Ventures, T. Rowe Price, and WestRiver Capital, along with returning backers Dr. Alejandro Zaffaroni (an Alexza co-founder), Frazier Healthcare, Versant Ventures, 5AM Ventures, Burrill & Co., CMEA Ventures, New Enterprise Associates, and clients of the Zesiger Capital Group.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alexza brings in $52mm with venture financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice